Searchable abstracts of presentations at key conferences in endocrinology

ea0098c5 | Clinical – Chemo/SSA/Biologics | NANETS2023

A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial

Jimenez Camilo , Habra Mouhammed A. , Campbell Matthew T. , Tamsen Gina , Cruz-Goldberg Damaris , Long James , Bassett Roland , Dantzer Robert , Balderrama Vania , Varghese Jeena , Waguespack Steven , Lu Yang

Background: Metastatic pheochromocytomas and paragangliomas are orphan neuroendocrine tumors. 50% of these tumors are associated with germline mutations of the SDHB gene. SDHB related pheochromocytomas and paragangliomas and many apparently sporadic tumors exhibit abnormal angiogenesis. This trial assessed the efficacy and safety of Cabozantinib, a potent, antiangiogenic, tyrosine kinase inhibitor. Methods: The Natalie trial is a single arm phase 2 clini...

ea0098c31 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

Al-Ward Ruaa , Balderrama Brondan Vania , Sawani Sahar , Bassett Roland , Xu Guofan , Waguespack Steven G. , Varghese Jeena , Amir Habra Mouhammed , Lu Yang , Jimenez Camilo

Background: Metastatic pheochromocytomas and paragangliomas are rare neuroendocrine tumors with limited treatment options. We studied the efficacy and safety of off-label High-Specific-Activity I-131-meta-iodobenzylguanidine (HSA-I-131-MIBG) in routine clinical practice. Methods: This is a retrospective cohort study. The primary endpoint is objective response rate (ORR) as per RECIST v1.1. Secondary endpoints are blood pressure control, safety, overall a...